To compare the result of inhaler vs nebulisation therapy while using NIV in acute exacerbation of COPD.
- Conditions
- Health Condition 1: J441- Chronic obstructive pulmonary disease with (acute) exacerbation
- Registration Number
- CTRI/2023/07/054734
- Lead Sponsor
- Pt. B. D. Sharma PGIMS Rohtak
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients aged >40 years.
2.Clinically suspected patients in AECOPD.
3.Patients of COPD in type 2 respiratory failure and pH between 7.25-7.35.
1.Any obstructive or restrictive respiratory disease other than COPD.
2.Hemodynamically unstable, defined as systolic blood pressure <90 mm Hg or mean arterial blood pressure <65 mm Hg despite appropriate volume resuscitation.
3.Patients in need of emergency intubation.
4.Arterial pH <7.25 or the pO2 below 45 mmHg despite oxygen therapy.
5.Patients in altered sensorium or Glasgow Coma Scale (GCS) less than 12.
6.Patients with facial deformity, trauma or surgery where proper oronasal mask seal cannot be ensured.
7.Patients with hypersensitivity to Levosalbutamol, coronary artery disease (CAD), tachyarrhythmias, and diabetic ketoacidosis (DKA).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To measure the level of Ipratropium Bromide in blood post aerosol therapy using pMDI versus jet nebulizer via face mask during NIV therapy.Timepoint: 30 minutes, 1 hour & 6 hours after aerosol therapy (prior to the next dose) in both arms.
- Secondary Outcome Measures
Name Time Method pH, pO2 & pCO2 will be measuredTimepoint: Before & after 2 hours of aerosol therapy in both arms.;Respiratory rate (RR), heart rate (HR) & oxygen saturation by pulse oximeter (SpO2) will be measuredTimepoint: 30 minutes, 1 hour & 6 hours after aerosol therapy (prior to the next dose) in both arms.